EPS for Align Technology, Inc. (ALGN) Expected At $0.96; 4 Analysts Are Bullish Penumbra, Inc. (PEN) Last Week

January 18, 2018 - By Louis Casey

Among 5 analysts covering Penumbra (NYSE:PEN), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Penumbra had 9 analyst reports since October 13, 2015 according to SRatingsIntel. Bank of America initiated Penumbra, Inc. (NYSE:PEN) on Wednesday, October 14 with “Buy” rating. The firm has “Buy” rating by Canaccord Genuity given on Monday, November 30. The firm has “Neutral” rating by JP Morgan given on Tuesday, January 2. The stock has “Buy” rating by Canaccord Genuity on Tuesday, October 13. BMO Capital Markets maintained Penumbra, Inc. (NYSE:PEN) on Wednesday, April 12 with “Buy” rating. On Tuesday, October 13 the stock rating was initiated by JP Morgan with “Overweight”. The rating was initiated by Wells Fargo on Tuesday, October 13 with “Outperform”. The stock of Penumbra, Inc. (NYSE:PEN) earned “Buy” rating by BMO Capital Markets on Thursday, May 11. See Penumbra, Inc. (NYSE:PEN) latest ratings:

02/01/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Neutral Downgrade

Analysts expect Align Technology, Inc. (NASDAQ:ALGN) to report $0.96 EPS on January, 30.They anticipate $0.29 EPS change or 43.28% from last quarter’s $0.67 EPS. ALGN’s profit would be $76.97M giving it 70.90 P/E if the $0.96 EPS is correct. After having $1.01 EPS previously, Align Technology, Inc.’s analysts see -4.95% EPS growth. The stock increased 3.17% or $8.37 during the last trading session, reaching $272.25. About 1.17M shares traded. Align Technology, Inc. (NASDAQ:ALGN) has risen 82.22% since January 18, 2017 and is uptrending. It has outperformed by 65.52% the S&P500.

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company has market cap of $3.04 billion. The firm offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, PX SLIM, and Velocity brands; aspiration based thrombectomy systems and accessory devices under the Penumbra System brand; and revascularization device for mechanical thrombectomy under the 3D brand. It currently has negative earnings. It also provides neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands; and neurovascular stents for stent-assisted coiling in large and wide-neck aneurysms under the LIBERTY Stent brand.

The stock increased 2.58% or $2.25 during the last trading session, reaching $89.45. About 161,679 shares traded. Penumbra, Inc. (NYSE:PEN) has risen 65.49% since January 18, 2017 and is uptrending. It has outperformed by 48.79% the S&P500.

Align Technology, Inc. designs, manufactures, and markets a system of clear aligner therapy, intra-oral scanners, and computer-aided design and computer-aided manufacturing digital services. The company has market cap of $21.83 billion. The companyÂ’s Clear Aligner segment offers Invisalign Full, a treatment used for a range of malocclusion; Invisalign Teen treatment that addresses orthodontic needs of teenage patients, such as compliance indicators, compensation for tooth eruption, and six free single arch replacement aligners; and Invisalign Assist treatment for anterior alignment and aesthetically-oriented cases. It has a 82.48 P/E ratio. It also provides Invisalign Express (10 and 5) and Invisalign Lite/i7 treatments for orthodontic cases, non-comprehensive treatment relapse cases, or straightening prior to restorative or cosmetic treatments; Invisalign Go, a solution for general practitioner dentists (GPs) to identify and treat patients with mild malocclusion; SmileDirectClub aligners for minor tooth movement; custom clear aligner retainers used to maintain tooth position and correct minor relapse; and SmartTrack, a custom-engineered material that delivers force for orthodontic tooth movements.

Investors sentiment decreased to 0.93 in 2017 Q3. Its down 0.46, from 1.39 in 2017Q2. It turned negative, as 36 investors sold Align Technology, Inc. shares while 194 reduced holdings. 77 funds opened positions while 137 raised stakes. 62.92 million shares or 1.48% more from 62.01 million shares in 2017Q2 were reported. Northern Trust reported 989,307 shares. Hl Svcs Ltd Liability Corp reported 0.08% in Align Technology, Inc. (NASDAQ:ALGN). Adirondack Tru accumulated 10 shares. Raymond James & Associate stated it has 84,580 shares. Tru Of Vermont invested in 0.02% or 960 shares. Bedrijfstakpensioenfonds Voor De Media Pno holds 0.18% or 8,563 shares in its portfolio. C M Bidwell & Assoc Ltd reported 4,430 shares or 1.27% of all its holdings. Thompson Davis Incorporated owns 8 shares or 0% of their US portfolio. Jennison Associates Llc owns 450,239 shares or 0.09% of their US portfolio. Guggenheim Cap Limited Com reported 0.21% in Align Technology, Inc. (NASDAQ:ALGN). Moreover, Sumitomo Mitsui Trust Holdings has 0.07% invested in Align Technology, Inc. (NASDAQ:ALGN). Ls Inv Advisors Ltd Liability invested in 0.05% or 4,888 shares. Ent Financial Corporation accumulated 13 shares or 0% of the stock. Zacks Investment Mngmt holds 0.05% or 10,447 shares. Tiedemann Wealth Ltd owns 0.08% invested in Align Technology, Inc. (NASDAQ:ALGN) for 16,602 shares.

Among 12 analysts covering Align Technology (NASDAQ:ALGN), 11 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Align Technology had 47 analyst reports since July 27, 2015 according to SRatingsIntel. The rating was initiated by Credit Suisse on Wednesday, May 11 with “Outperform”. Stifel Nicolaus maintained the stock with “Buy” rating in Friday, January 29 report. The stock has “Buy” rating by Piper Jaffray on Thursday, July 27. Credit Suisse maintained the shares of ALGN in report on Tuesday, November 28 with “Buy” rating. The rating was maintained by Jefferies with “Buy” on Wednesday, September 13. The stock has “Buy” rating by Stifel Nicolaus on Sunday, August 6. The rating was downgraded by Robert W. Baird on Monday, October 3 to “Neutral”. The rating was maintained by Jefferies on Tuesday, July 4 with “Buy”. The rating was maintained by Stifel Nicolaus on Monday, November 28 with “Buy”. Deutsche Bank initiated the stock with “Hold” rating in Friday, December 8 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: